Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : BJCT-BIOJECT-needle less injection product -- Ignore unavailable to you. Want to Upgrade?

To: Arthur S. Conroy who wrote (223)	7/13/1998 10:51:00 AM
From: James Strauss	Read Replies (1) \| Respond to of 534

This is big news...!!!! Monday July 13, 8:51 am Eastern Time Company Press Release SOURCE: Bioject Medical Technologies Inc. Bioject Enters Vaccine Agreement With Merck PORTLAND, Ore., July 13 /PRNewswire/ -- Bioject Medical Technologies Inc. (Nasdaq: BJCT - news), the leading manufacturer of jet injection devices for needle- free intradermal, subcutaneous and intramuscular injections, today announced it has entered into an agreement that provides Merck & Co. (NYSE: MRK - news) with the rights to use its jet injection system to deliver selected Merck vaccines. The terms of the agreement were not disclosed. Said Jim O'Shea, chairman, president and chief executive officer of Bioject: ''This alliance underscores the tremendous potential of our unique needle-free technologies. The Biojector 2000 is the only needle-free injector available today that is capable of delivering intradermal, subcutaneous and intramuscular injections.'' O'Shea continued: ''We're delighted to be working with an industry leader such as Merck, and are optimistic about the relationship. This agreement marks a significant step forward in our strategy to grow through corporate partnerships aimed at developing new applications for our technologies, and we intend to build on this partnership and others to benefit our shareholders, employees and customers.'' Bioject develops, manufactures and markets jet injection systems for needle-free delivery of pharmaceutical agents. The Company's advanced injection management system, the Biojector 2000, has received the Seal of Acceptance from the Alliance of Children's Hospitals, Inc. The Company is developing a system for Hoffmann-La Roche to market specifically with their products. Bioject is also developing an ambulatory continuous blood glucose- monitoring system for diabetics through Marathon Medical Technologies, its joint venture with Elan Corporation. The forward-looking statements contained in this release are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward looking statements. Readers of this press release are referred to the company's filings with the Securities and Exchange Commission, including the company's Annual Report on Form 10-K for the year ended March 31, 1998 for further discussions of factors which could affect future results. SOURCE: Bioject Medical Technologies Inc. More Quotes and News: Bioject Medical Technologies Inc (Nasdaq:BJCT - news) Merck & Co Inc (NYSE:MRK - news) Related News Categories: medical/pharmaceutical Jim